Corcept Therapeutics Incorporated (CORT)

Corcept Therapeutics Stock Forecast

Stock Price Forecast

The 5 analysts that cover Corcept Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $86.25, which forecasts a 56.48% increase in the stock price over the next year. The lowest target is $72 and the highest is $110.

Price Target: $86.25 (+56.48%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$72	$86.25	n/a	$110
Change	+30.62%	+56.48%	n/a	+99.56%

Analyst Ratings

The average analyst rating for Corcept Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26	May '26
Strong Buy	3	3	3	3	3	3
Buy	1	1	1	1	1	1
Hold	2	2	2	2	2	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	6	6	6	6	6	5

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Ashwani Verma UBS	UBS	Hold → Strong Buy Upgrades $44 → $72	Hold → Strong Buy	Upgrades	$44 → $72	+30.62%	May 13, 2026
Swayampakula Ramakanth HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $60 → $75	Strong Buy	Maintains	$60 → $75	+36.07%	May 4, 2026
David Amsellem Piper Sandler	Piper Sandler	Buy Maintains $73 → $88	Buy	Maintains	$73 → $88	+59.65%	May 1, 2026
Edward Nash Canaccord Genuity	Canaccord Genuity	Strong Buy Maintains $100 → $110	Strong Buy	Maintains	$100 → $110	+99.56%	Mar 26, 2026
Kalpit Patel Wolfe Research	Wolfe Research	Sell → Hold Upgrades n/a	Sell → Hold	Upgrades	n/a	n/a	Mar 26, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

979.92M

Increased by 28.70%

from 761.41M

Revenue Next Year

1.23B

Increased by 25.32%

from 979.92M

EPS This Year

0.54

Decreased by -33.82%

from 0.82

EPS Next Year

1.52

Increased by 180.39%

from 0.54

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	365.98M	401.86M	482.38M	675.04M	761.41M	979.92M	1.23B
Revenue Growth	3.42%	9.80%	20.04%	39.94%	12.79%	28.70%	25.32%
EPS	0.89	0.87	0.94	1.23	0.82	0.54	1.52
EPS Growth	4.71%	-2.25%	8.05%	30.85%	-33.33%	-33.82%	180.39%
Forward PE	-	-	-	-	-	101.58	36.23
No. Analysts	-	-	-	-	-	8	8

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027	2028	2029	2030	2031	2032	2033
High	1.1B	1.5B
Avg	979.9M	1.2B
Low	886.9M	949.5M

Revenue Growth

Revenue Growth	2026	2027	2028	2029	2030	2031	2032	2033
High	41.4%	55.1%
Avg	28.7%	25.3%
Low	16.5%	-3.1%

EPS Forecast

EPS	2026	2027	2028	2029	2030	2031	2032	2033
High	0.93	3.15
Avg	0.54	1.52
Low	0.20	0.35

EPS Growth

EPS Growth	2026	2027	2028	2029	2030	2031	2032	2033
High	14.0%	480.5%
Avg	-33.8%	180.4%
Low	-76.1%	-35.0%

Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.